Product Information
LOTEMAX 0.5% EYE OINTMENT is a brand product labeled by Bausch & Lomb Incorporated, priced at $99.7438 per GM under NDC 24208044335. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Apr 15, 2011.
The High Outlier badge above means this manufacturer's average price in the loteprednol etabonate market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
5 mg/g
Manufacturer
Bausch & Lomb IncorporatedNDC
24208044335
Classification
Brand
Dosage Form
OINTMENT
Route
OPHTHALMIC
Effective Date
9/23/2026
Active Ingredients
LOTEPREDNOL ETABONATEApproval Type
New Drug (NDA)
FDA Application
NDA200738FDA Approved
4/15/2011
On Market Since
4/15/2011
Pharmacological Classes
Price Statistics
The NADAC for LOTEMAX 0.5% EYE OINTMENT has been published 671 times since Nov 28, 2013, and over the history we have for it it has risen 113.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $99.7438 per GM |
|---|---|
| All-time high | $100.0617 (May 14, 2025) |
| All-time low | $46.6494 (Nov 28, 2013) |
| 52-week high | $99.8040 |
| 52-week low | $99.6379 |
| Median price | $77.8710 |
| Average price | $77.3635 |
| Largest weekly change | +10.0% (Jan 14, 2015) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the loteprednol etabonate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Bausch & Lomb Incorporated manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
loteprednol etabonate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Corticosteroid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LOTEMAX 0.5% EYE OINTMENT?
The current National Average Drug Acquisition Cost (NADAC) for LOTEMAX 0.5% EYE OINTMENT, manufactured by Bausch & Lomb Incorporated, is $99.7438 per GM (NDC 24208044335), effective Sep 30, 2026.
How has the price of LOTEMAX 0.5% EYE OINTMENT changed over time?
Over the history we have for it, the NADAC for LOTEMAX 0.5% EYE OINTMENT has risen 113.8%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for LOTEMAX 0.5% EYE OINTMENT?
Since Nov 28, 2013, the NADAC for LOTEMAX 0.5% EYE OINTMENT has ranged from a low of $46.6494 (Nov 28, 2013) to a high of $100.0617 (May 14, 2025), with a median of $77.8710 per GM.
Are there cheaper alternatives to LOTEMAX 0.5% EYE OINTMENT?
No other NADAC-published product currently shares the active ingredient and strength of LOTEMAX 0.5% EYE OINTMENT in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures LOTEMAX 0.5% EYE OINTMENT?
LOTEMAX 0.5% EYE OINTMENT (NDC 24208044335) is labeled by Bausch & Lomb Incorporated, and CMS classifies it as a brand product.